Navigation Links
Clinical studies in the pipeline: the therapies of tomorrow in trials today
Date:10/23/2007

itinib may indeed target key angiogenesis pathways in relevant cell populations.

These are very interesting changes in blood markers induced by sunitinib. Ongoing studies of these and of other markers might help us to understand how the drug works in HCC and what changes might be relevant in predicting the potential clinical benefits in these patients, Dr. Zhu said.

The Harvard Medical School research team involved in this study includes Dushyant Sahani, M.D., and Rakesh K. Jain, Ph.D. The study was funded by Pfizer, Inc., manufacturers of sunitinib (marketed as Sutent).

Recombinant IL-21 in combination with sorafenib: Preliminary results from a phase I/II study in patients with metastatic renal cell cancer: Abstract A 60.

Two drugs appear to work better than one in treatment of patients with metastatic kidney cancer, according to early results from the first and only clinical trial testing a combination of sorafenib and recombinant interleukin-21.

Among 11 patients with renal cell carcinoma who have gone on to have two or more rounds of combination treatment, 10 have experienced tumor shrinkage, and four patients have had 30 percent or greater reduction in tumor size as measured by the investigators. A total of 13 patients have been enrolled so far in this Phase I study, which is testing three different dose levels.

These preliminary data are encouraging, as treatment with sorafenib alone was associated with a confirmed overall response rate of only two percent in the Phase III trial that led to regulatory approval, said the studys lead investigator, John A. Thompson, M.D., a professor of medicine at the University of Washington and a member of the Fred Hutchinson Cancer Research Center. The study was funded by Zymogenetics, which developed recombinant interleukin-21 (IL-21).

However, at this point the number of patients treated in our study is still small and it is too early to draw a definite
'/>"/>

Contact: Greg Lester
greg.lester@aacr.org
267-646-0554
American Association for Cancer Research
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related medicine news :

1. How do patients benefit of clinical trials
2. Magnetic resonance angiography in clinical medicine
3. Clinical trials need to be more frank
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
6. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
7. Clinical Comparisons Between ADHD Drugs Are Less
8. Outsourcing clinical trials to India
9. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
10. India to maintain Public domain Registry database of clinical trials conducted in India.
11. A Novel System For Clinical Banking Of Umbilical Cord Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... rats exposed to high-energy particles, simulating conditions astronauts would ... in attention and slower reaction times, even when the ... The cognitive impairments which affected a large subset, ... to be linked to protein changes in the brain, ... true in humans, suggest it may be possible to ...
(Date:4/23/2014)... the gastro-intestinal tract has long been considered to be ... Sahlgrenska Academy have used refined microscopic techniques that indicate ... of the gastro-intestinal tract is only as large as ... The digestive tract, which passes from the mouth through ... length of about 5 meters in a normal adult, ...
(Date:4/23/2014)... The American Gastroenterological Association (AGA) Research Foundation is ... The AGA Research Scholar Awards program, launched in ... productive research careers in digestive diseases. This year, ... year allowing for three consecutive years of funding. ... who are paving the way for promising research ...
(Date:4/23/2014)... SEATTLE, Washington, April 21, 2014 Five for-profit ... total of $1.25 million in Proof of Concept ... from ideas into commercial products, the Life Sciences ... a $300,000 Entrepreneur Mentoring Program grant to the ... a statewide advisory network to train the next ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
Breaking Medicine News(10 mins):Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
... to a new study in Clinical Gastroenterology and ... could help physicians know which patients will benefit most ... and Hepatology is the official journal of the ... or cholecystectomies, are performed annually in the U.S. at ...
... taking folic acid supplements during pregnancy reduces the risk ... little is known about the relationship between prenatal folic ... between investigators at the Norwegian Institute of Public Health ... now reported that mothers who took folic acid supplements ...
... , TUESDAY, Oct. 11 (HealthDay News) -- Studies ... injury are plagued by design problems, a new report issued ... upshot: While evidence exists that this kind of therapy helps ... strong enough to develop definitive guidelines for its use. ...
... -- Men who become parents later in life are not ... study suggests. Researchers in Sweden found children born to ... kids with fathers in their 30s. The findings, they noted, ... have a negative impact on his children,s IQ. In ...
... E supplement a regimen once thought to reduce cancer ... to results of a large national study. The finding ... Selenium and,Vitamin E Cancer Prevention Trial (SELECT). Eric Klein, M.D., ... Clinic, is the lead author. SELECT began in 2001 ...
... Oct. 11 (HealthDay News) -- A small, preliminary study finds that ... a potential sign that the pills might reduce the risk of ... and the researchers aren,t yet recommending that people head to the ... "If you want to add ginger to part of a ...
Cached Medicine News:Health News:Pain characteristics suggest higher benefit from gallbladder surgery 2Health News:Folic acid supplements in early pregnancy may reduce the risk of severe language delay in children 2Health News:Evidence Lacking That Cognitive Rehab Therapy Helps Brain-Injured Vets 2Health News:Evidence Lacking That Cognitive Rehab Therapy Helps Brain-Injured Vets 3Health News:National study finds vitamin E supplement may increase prostate cancer risk 2Health News:Ginger Supplements Might Ease Inflammation Linked to Colon Cancer 2
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
(Date:1/15/2014)... AARP Foundation today announced it has established a relief ... cold weather that has gripped much of the nation. AARP ... so to support these emergency relief efforts AARP and AARP ... mean up to $500,000 in aid. The matching program will ...
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... NEW YORK, Oct. 25, 2011 Reportlinker.com ... is available in its catalogue: ... Market Forecasts to 2018 ... - Pipeline Assessment and Market Forecasts to ...
... YORK, Oct. 25, 2011 Reportlinker.com ... report is available in its catalogue: ... Market to 2017 - Patent Expiries ... Aricept, Namenda, Avonex, Rebif and Copaxone ...
Cached Medicine Technology:Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 2Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 3Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 4Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 5Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 6Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 7Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 8Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 9Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 10Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 11Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 2Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 3Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 4Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 5Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 6Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 7Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 8Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 9Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 10Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 11Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 13Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 14Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 15
...
...
...
... plate system features an advanced design that ... Trinica system gives surgeons the flexibility to ... anatomy. Flexibility is built-in to every aspect ... the innovative Secure-Twist anti-migration system to the ...
Medicine Products: